Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Heart Team therapeutic decision-making and treatment in severe aortic valve stenosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Atrial fibrillation and anticoagulation in patients with breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Role of Pannexin and adenosine triphosphate (ATP) following myocardial ischemia/reperfusion

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Use of renal replacement therapy after out-of-hospital cardiac arrest in Denmark 2005-2013

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnostic Potential of Intracardiac Echocardiography in Patients with Suspected Prosthetic Valve Endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mortality and morbidity of major congenital heart disease related to general prenatal screening for malformations

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objectives After transcatheter aortic valve implantation (TAVI) has been available for high-risk patients with severe aortic valve stenosis (AVS), the decision-making of the Heart Team (HT) has not been examined. Design All adult patients with severe AVS referred to a large tertiary medical centre in 2011 were prospectively included. Multivariate regression analysis identified independent factors associated with treatment decisions. Results A total of 487 patients were included (mean age: 75 years, NYHA class III-IV: 47%). The HT proposed medical therapy (MT) in 35 (7%), TAVI in 60 (12%), and surgical aortic valve replacement (SAVR) in 392 (81%) of patients. In patients referred to intervention, TAVI compared with SAVR patients were older (OR = 1.17 per year, 95% CI 1.09-1.26; p < 0.01) with more previous coronary artery bypass surgery (OR = 385, 79-2738; p < 0.01), obesity (OR = 4.69, 1.51-13.77; p < 0.01), and chronic obstructive pulmonary disease (COPD) (OR = 3.66, 1.21-10.75; p = 0.02). MT patients compared with patients referred to any intervention were older, had a higher prevalence of COPD, peripheral arterial disease, previous myocardial infarction, and cerebrovascular disease. Conclusions The HT proposed intervention in 93% of patients with severe AVS despite high age, advanced symptoms and a high burden of co-morbidity. TAVI was reserved for older patients particularly with previous CABG.

Original languageEnglish
JournalScandinavian cardiovascular journal : SCJ
Volume50
Issue number3
Pages (from-to)146-53
Number of pages8
ISSN1401-7431
DOIs
Publication statusPublished - Jun 2016

    Research areas

  • Journal Article

ID: 49804600